{"url_path":"/sec/cdio/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1870144/0001553350-26-000089-index.html","accession_number":"0001553350-26-000089","cik":"0001870144","ticker":"CDIO","issuer_name":"Cardio Diagnostics Holdings, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1870144/0001553350-26-000089-index.html","primary_entity_key":"0001870144","primary_entity_name":"Cardio Diagnostics Holdings, Inc."},"word_count":763,"has_tables":true,"body_markdown":"10-Q\n\nfalse\n--12-31\nQ1\n2026\n0001870144\n\n0001870144\n\n2026-01-01\n2026-03-31\n\n0001870144\n\ncdio:CommonStockParValue0.00001PerShareMember\n\n2026-01-01\n2026-03-31\n\n0001870144\n\ncdio:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001870144\n\n2026-05-15\n\n0001870144\n\n2026-03-31\n\n0001870144\n\n2025-12-31\n\n0001870144\n\n2025-01-01\n2025-03-31\n\n0001870144\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001870144\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001870144\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001870144\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001870144\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001870144\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001870144\n\n2024-12-31\n\n0001870144\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001870144\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001870144\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001870144\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001870144\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001870144\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001870144\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001870144\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001870144\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001870144\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001870144\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001870144\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001870144\n\n2025-03-31\n\n0001870144\n\n2025-05-01\n2025-05-12\n\n0001870144\n\n2025-05-12\n\n0001870144\n\ncdio:ReportableSegmentsMember\n\n2026-03-31\n\n0001870144\n\ncdio:ReportableSegmentsMember\n\n2025-12-31\n\n0001870144\n\ncdio:ReportableSegmentsMember\ncdio:ProductTestSalesMember\n\n2026-01-01\n2026-03-31\n\n0001870144\n\ncdio:ReportableSegmentsMember\ncdio:ProductTestSalesMember\n\n2025-01-01\n2025-03-31\n\n0001870144\n\ncdio:ReportableSegmentsMember\n\n2026-01-01\n2026-03-31\n\n0001870144\n\ncdio:ReportableSegmentsMember\n\n2025-01-01\n2025-03-31\n\n0001870144\n\nus-gaap:PatentsMember\n\n2026-03-31\n\n0001870144\n\nus-gaap:PatentsMember\n\n2025-12-31\n\n0001870144\n\nus-gaap:PatentsMember\n\n2026-01-01\n2026-03-31\n\n0001870144\n\nus-gaap:PatentsMember\n\n2025-01-01\n2025-03-31\n\n0001870144\n\n2023-08-02\n2023-11-30\n\n0001870144\n\n2024-01-16\n\n0001870144\n\n2023-12-31\n\n0001870144\n\ncdio:ChicagoMember\n\n2023-01-01\n2023-12-31\n\n0001870144\n\nstpr:IA\n\n2023-01-01\n2023-12-31\n\n0001870144\n\ncdio:LeaseOneMember\n\n2026-03-31\n\n0001870144\n\ncdio:LeaseTwoMember\n\n2026-03-31\n\n0001870144\n\ncdio:LeaseOneMember\n\n2025-12-31\n\n0001870144\n\ncdio:LeaseTwoMember\n\n2025-12-31\n\n0001870144\n\n2024-10-01\n2024-10-25\n\n0001870144\n\n2024-10-25\n\n0001870144\n\n2025-10-25\n\n0001870144\n\n2025-10-01\n2025-10-25\n\n0001870144\n\n2026-10-25\n\n0001870144\n\ncdio:StockWarrantsMember\n\n2026-01-01\n2026-03-31\n\n0001870144\n\ncdio:StockWarrantsMember\n\n2025-01-01\n2025-03-31\n\n0001870144\n\ncdio:StockOptionsMember\n\n2026-01-01\n2026-03-31\n\n0001870144\n\ncdio:StockOptionsMember\n\n2025-01-01\n2025-03-31\n\n0001870144\n\ncdio:N2022PlanMember\n\n2026-03-31\n\n0001870144\n\ncdio:N2022PlanMember\n\n2024-01-23\n\n0001870144\n\ncdio:N2022PlanMember\n\n2025-03-31\n\n0001870144\n\ncdio:AtTheMarketIssuanceMember\ncdio:SalesAgreementMember\n\n2026-01-01\n2026-03-31\n\n0001870144\n\ncdio:AtTheMarketIssuanceMember\ncdio:SalesAgreementMember\n\n2025-01-01\n2025-03-31\n\n0001870144\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2025-01-01\n2025-03-31\n\n0001870144\n\nus-gaap:StockOptionMember\ncdio:BoardOfDirectorsMember\n\n2025-01-01\n2025-03-31\n\n0001870144\n\ncdio:StockOptionsMember\n\n2025-01-01\n2025-03-31\n\n0001870144\n\ncdio:StockOptionsMember\n\n2025-03-31\n\n0001870144\n\ncdio:StockOptionsMember\n\n2026-01-01\n2026-03-31\n\n0001870144\n\ncdio:StockOptionsMember\n\n2026-03-31\n\n0001870144\n\nus-gaap:WarrantMember\n\n2024-12-31\n\n0001870144\n\nus-gaap:WarrantMember\n\n2024-01-01\n2024-12-31\n\n0001870144\n\nus-gaap:WarrantMember\n\n2025-01-01\n2025-03-31\n\n0001870144\n\nus-gaap:WarrantMember\n\n2025-03-31\n\n0001870144\n\nus-gaap:WarrantMember\n\n2025-12-31\n\n0001870144\n\nus-gaap:WarrantMember\n\n2025-01-01\n2025-12-31\n\n0001870144\n\nus-gaap:WarrantMember\n\n2026-01-01\n2026-03-31\n\n0001870144\n\nus-gaap:WarrantMember\n\n2026-03-31\n\n0001870144\n\ncdio:StockOptionsMember\n\n2024-12-31\n\n0001870144\n\ncdio:StockOptionsMember\n\n2024-01-01\n2024-12-31\n\n0001870144\n\ncdio:StockOptionsMember\n\n2025-12-31\n\n0001870144\n\ncdio:StockOptionsMember\n\n2025-01-01\n2025-12-31\n\n0001870144\n\ncdio:TheBenchmarkCompanyLLCMember\n\n2026-01-01\n2026-03-31\n\n0001870144\n\ncdio:NorthlandSecuritiesMember\n\n2024-01-01\n2024-01-31\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE\nCOMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 10-Q**\n\n \n\n(Mark One)\n\n \n\n☒\n  **QUARTERLY REPORT PURSUANT TO ****SECTION ****13 OR 15(d) OF THE ****SECURITIES ****EXCHANGE ****ACT ****OF 1934**\n\n \n\n**For\nthe quarterly period ended March 31, 2026**\n\n \n\n☐  \n**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For the\ntransition period from _____ to _____**\n\n \n\n**Commission File Number:** **001-41097**\n\n \n\n**Cardio Diagnostics Holdings, Inc.**\n\n(Exact name of registrant\nas specified in its charter)\n\n \n\n**Delaware**\n \n**87-0925574**\n\n(State or other jurisdiction of\n\nincorporation or organization)\n\n \n\n(I.R.S. Employer\n\nIdentification No.)\n\n \n\n**311 West Superior Street, Suite 444**\n\n**Chicago, Illinois**\n\n \n**60654**\n\n(Address of principal executive offices)\n \n(Zip Code)\n\n \n\n**(855) 226-9991**\n\n**(**Registrant’s\ntelephone number, including area code)\n\n \n\n(Former name or former\naddress, if changed since last report)\n\n \n\n \n\nSecurities registered\npursuant to Section 12(b) of the Act:\n\n \n\n**Title of each class**\n \n**Trading Symbol(s)**\n \n\n**Name of each exchange on**\n\n**which registered**\n\nCommon Stock, par value $0.00001 per share\n \nCDIO\n \nThe NASDAQ Stock Market LLC\n\nRedeemable Warrants, each whole warrant exercisable for one share of Common Stock\n \nCDIOW\n \nThe NASDAQ Stock Market LLC\n\n \n\nIndicate\nby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange\nAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\nhas been subject to such filing requirements for the past 90 days. Yes ☒\nNo ☐\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule\n405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant\nwas required to submit such files). Yes ☒ No\n☐\n\n \n\nIndicate by check mark\nwhether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an\nemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller\nreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer\n☐\nAccelerated filer\n☐\n\n \n \n \n \n\nNon-accelerated filer\n☒\nSmaller reporting company\n☒\n\n \n \n \n \n\n \n \nEmerging growth company\n☒\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No\n☒\n\n \n\nAs of May 15, 2026, there\nwere 2,959,469 shares of the registrant’s Common Stock, $0.00001 par value, issued and outstanding.\n\n \n\n \n\n \n\n \n\n  \n\n**CARDIO DIAGNOSTICS\nHOLDINGS, INC.**\n\n \n\n**FORM 10-Q**\n\n**For the Quarter Ended\nMarch 31, 2026**\n\n \n\n**TABLE OF CONTENTS**\n\n \n\n[Introductory Note](#a_001)\nii\n\n[Note About Forward-Looking Statements](#a_001)\nii\n\n \n \n\nPart I — Financial Information"}